Why is Cohance Life falling/rising?

As of 26-Aug, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 885.90, which reflects a decrease of Rs 12.25 or 1.36%. The stock is close to its 52-week low, being only 0.94% away from Rs 877.55, and it has underperformed the market significantly over the past year with a return of -17.37% compared to the Sensex's -1.12%. Despite a notable increase in delivery volume by 102.69% on 25 August, the stock is trading below all its moving averages, indicating a bearish trend. Additionally, while the company boasts a high return on equity (ROE) of 24.14% and a low debt-to-equity ratio, it faces challenges such as poor long-term growth, flat quarterly results, and a high proportion of pledged promoter shares, which can exert downward pressure on the stock.
In the broader market context, Cohance Lifesciences has seen a 3.92% decline over the past week, while the Sensex has only fallen by 1.05%, highlighting the stock's relative weakness. The company's operating profit growth has been stagnant at an annual rate of 2.95% over the last five years, and its recent quarterly results show a significant drop in profit after tax (PAT) by 41.1%. The stock's valuation is considered expensive with a price-to-book ratio of 20, further complicating its appeal to investors. Overall, the combination of poor performance metrics, high pledged shares, and underperformance relative to the market contributes to the stock's current downward trajectory.